Guanghai Dai

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zixian Wang, Chengxu Cui, Jun Yao et al. · Cancer Cell · 2022 · 565 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

F. Wang, Xiaoli Wei, Fenggong Wang et al. · Annals of Oncology · 2019 · 476 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Feng‐Hua Wang, Xiaoli Wei, Jifeng Feng et al. · Journal of Clinical Oncology · 2021 · 351 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

Shukui Qin, Jin Li, Liwei Wang et al. · Journal of Clinical Oncology · 2018 · 257 citations · Full text

Medicine, Oncology, Pharmacology +12

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Zhi Peng, Tianshu Liu, Jia Wei et al. · Cancer Communications · 2021 · 202 citations · Full text

Medicine, Oncology, Pharmacology +16